Price
No data yet.
Social Signal Score
Analyst Ratings
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Erez Aminov
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Beta
- -0.25
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 131.34
Financials
Net Income
$-1.72MEBITDA
$-1.72MFree Cash Flow
$-1.01MEPS (diluted)
$-1.39Shares Outstanding (diluted)
34.38M+16.1%Operating Expenses
$1.76MCash & Debt
$5.17MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-10.41M | $-0.33 |
| 2024 | $0.00 | $-16.53M | $-0.56 |
| 2023 | $0.00 | $-13.07M | $-0.44 |
| 2022 | $0.00 | $-854.1K | $-0.03 |
| 2021 | $0.00 | $-138.1K | $-0.00 |
Valuation
TELOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (3)
- Newsnewsfilecorp.com·7d ago·Neutral
Telo Genomics Reports Additional Clinical Research Results Comparing Blood-Based TELO-MRD with Bone-Marrow Next-Generation Flow and Next-Generation Sequencing In matched Cleveland Clinic and Jewish General Hospital samples, blood-based TELO enumeration detected circulating plasma cells in all Adaptive clonoSEQ-positive cases reviewed and in a series of clonoSEQ-negative or non-evaluable samples; previously reported EuroFlow comparison data are also summarized. Vancouver, British Columbia--(Newsf…
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
…y Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models MIAMI, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer, announced new research findings from The Ohio State University College of Veterinary Medicine demonstrating that Telomir-Zn produces inhibition of cell growth across human and canine osteosarcoma…
View source ↗ - Newsdefenseworld.net·55d ago·Negative
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4% – Should You Sell? Shares of Telomir Pharmaceuticals, Inc. (NASDAQ: TELO - Get Free Report) were down 3.4% during mid-day trading on Tuesday. The company traded as low as $1.13 and last traded at $1.13. 27,578 shares traded hands during trading, a decline of 74% from the average daily volume of 104,128 shares. The stock had previously closed at
View source ↗
Earnings
Wed, Dec 2(in 8 weeks)
Consensus estimate $-0.03 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.79 vs $-0.07miss
- Wed, May 13$-0.03 vs $-0.07beat
- Tue, Mar 17$-0.06 vs $-0.07beat
- Mon, Nov 10$-0.03 vs $-0.07beat
- Thu, Aug 14$-0.17 vs $-0.08miss
- Wed, May 14$-0.07 vs $-0.10beat
Estimates and results for TELO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TELO officers and directors.
- Bought
- $966k
- Sold
- $2k
3 trades
2 trades
- Aminov Erezsold
- Aminov Erezsold
- Bay Shore Trustbought
- Bay Shore Trustbought
- Bay Shore Trustbought
45 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in TELO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.